BACKGROUND: Healthy volunteer wild-type influenza challenge models offer a unique opportunity to evaluate multiple aspects of this important virus. Such studies have not been performed in the United States in more than a decade, limiting our capability to investigate this virus and develop countermeasures. We have completed the first ever wild-type influenza A challenge study under an Investigational New Drug application (IND). This dose-finding study will lead to further development of this model both for A(H1N1)pdm09 and other strains of influenza. METHODS: Volunteers were admitted to an isolation unit at the National Institutes of Health Clinical Center for a minimum of 9 days. A reverse genetics, cell-based, Good Manufacturing Practice (GMP)-produced, wild-type A(H1N1)pdm09 virus was administered intranasally. Escalating doses were given until a dose was reached that produced disease in a minimum of 60% of volunteers. RESULTS: An optimal dose of 10(7) tissue culture infectious dose 50 was reached that caused mild to moderate influenza disease in 69% of individuals with mean viral shedding for 4-5 days and significant rises in convalescent influenza antibody titers. Viral shedding preceded symptoms by 12-24 hours and terminated 2-3 days prior to symptom resolution, indicating that individuals may be infectious before symptom development. As expected, nasal congestion and rhinorrhea were most common, but interestingly, fever was observed in only 10% of individuals. CONCLUSIONS: This study represents the first healthy volunteer influenza challenge model using a GMP-produced wild-type virus under an IND. This unique clinical research program will facilitate future studies of influenza pathogenesis, animal model validation, and the rapid, efficient, and cost-effective evaluation of efficacy of novel vaccines and therapeutics. Clinical Trials Registration.NCT01646138. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Healthy volunteer wild-type influenza challenge models offer a unique opportunity to evaluate multiple aspects of this important virus. Such studies have not been performed in the United States in more than a decade, limiting our capability to investigate this virus and develop countermeasures. We have completed the first ever wild-type influenza A challenge study under an Investigational New Drug application (IND). This dose-finding study will lead to further development of this model both for A(H1N1)pdm09 and other strains of influenza. METHODS: Volunteers were admitted to an isolation unit at the National Institutes of Health Clinical Center for a minimum of 9 days. A reverse genetics, cell-based, Good Manufacturing Practice (GMP)-produced, wild-type A(H1N1)pdm09 virus was administered intranasally. Escalating doses were given until a dose was reached that produced disease in a minimum of 60% of volunteers. RESULTS: An optimal dose of 10(7) tissue culture infectious dose 50 was reached that caused mild to moderate influenza disease in 69% of individuals with mean viral shedding for 4-5 days and significant rises in convalescent influenza antibody titers. Viral shedding preceded symptoms by 12-24 hours and terminated 2-3 days prior to symptom resolution, indicating that individuals may be infectious before symptom development. As expected, nasal congestion and rhinorrhea were most common, but interestingly, fever was observed in only 10% of individuals. CONCLUSIONS: This study represents the first healthy volunteer influenza challenge model using a GMP-produced wild-type virus under an IND. This unique clinical research program will facilitate future studies of influenza pathogenesis, animal model validation, and the rapid, efficient, and cost-effective evaluation of efficacy of novel vaccines and therapeutics. Clinical Trials Registration.NCT01646138. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
H1N1; challenge; healthy volunteer; influenza; influenza A
Authors: A E Krafft; K L Russell; A W Hawksworth; S McCall; M Irvine; L T Daum; J L Connoly; A H Reid; J C Gaydos; J K Taubenberger Journal: J Clin Microbiol Date: 2005-04 Impact factor: 5.948
Authors: F G Hayden; J J Treanor; R S Fritz; M Lobo; R F Betts; M Miller; N Kinnersley; R G Mills; P Ward; S E Straus Journal: JAMA Date: 1999-10-06 Impact factor: 56.272
Authors: Fabrice Carrat; Elisabeta Vergu; Neil M Ferguson; Magali Lemaitre; Simon Cauchemez; Steve Leach; Alain-Jacques Valleron Journal: Am J Epidemiol Date: 2008-01-29 Impact factor: 4.897
Authors: Rebecca J Garten; C Todd Davis; Colin A Russell; Bo Shu; Stephen Lindstrom; Amanda Balish; Wendy M Sessions; Xiyan Xu; Eugene Skepner; Varough Deyde; Margaret Okomo-Adhiambo; Larisa Gubareva; John Barnes; Catherine B Smith; Shannon L Emery; Michael J Hillman; Pierre Rivailler; James Smagala; Miranda de Graaf; David F Burke; Ron A M Fouchier; Claudia Pappas; Celia M Alpuche-Aranda; Hugo López-Gatell; Hiram Olivera; Irma López; Christopher A Myers; Dennis Faix; Patrick J Blair; Cindy Yu; Kimberly M Keene; P David Dotson; David Boxrud; Anthony R Sambol; Syed H Abid; Kirsten St George; Tammy Bannerman; Amanda L Moore; David J Stringer; Patricia Blevins; Gail J Demmler-Harrison; Michele Ginsberg; Paula Kriner; Steve Waterman; Sandra Smole; Hugo F Guevara; Edward A Belongia; Patricia A Clark; Sara T Beatrice; Ruben Donis; Jacqueline Katz; Lyn Finelli; Carolyn B Bridges; Michael Shaw; Daniel B Jernigan; Timothy M Uyeki; Derek J Smith; Alexander I Klimov; Nancy J Cox Journal: Science Date: 2009-05-22 Impact factor: 47.728
Authors: Suzanne Jones; Kirsten Evans; Hilary McElwaine-Johnn; Michaela Sharpe; John Oxford; Rob Lambkin-Williams; Tim Mant; Andrew Nolan; Maria Zambon; Joanna Ellis; John Beadle; Peter T Loudon Journal: Vaccine Date: 2009-02-24 Impact factor: 3.641
Authors: Yongli Xiao; Jacqueline M Nolting; Zong-Mei Sheng; Tyler Bristol; Li Qi; Andrew S Bowman; Jeffery K Taubenberger Journal: Virology Date: 2018-09-10 Impact factor: 3.616
Authors: Jennifer L McKimm-Breschkin; Shibo Jiang; David S Hui; John H Beigel; Elena A Govorkova; Nelson Lee Journal: Antiviral Res Date: 2017-11-21 Impact factor: 5.970
Authors: Jae-Keun Park; Yongli Xiao; Mitchell D Ramuta; Luz Angela Rosas; Sharon Fong; Alexis M Matthews; Ashley D Freeman; Monica A Gouzoulis; Natalia A Batchenkova; Xingdong Yang; Kelsey Scherler; Li Qi; Susan Reed; Rani Athota; Lindsay Czajkowski; Alison Han; David M Morens; Kathie-Anne Walters; Matthew J Memoli; John C Kash; Jeffery K Taubenberger Journal: Nat Med Date: 2020-06-29 Impact factor: 53.440